Kang Sun

2.9k total citations · 3 hit papers
56 papers, 1.6k citations indexed

About

Kang Sun is a scholar working on Dermatology, Immunology and Allergy and Rheumatology. According to data from OpenAlex, Kang Sun has authored 56 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Dermatology, 21 papers in Immunology and Allergy and 9 papers in Rheumatology. Recurrent topics in Kang Sun's work include Dermatology and Skin Diseases (26 papers), Allergic Rhinitis and Sensitization (15 papers) and Urticaria and Related Conditions (9 papers). Kang Sun is often cited by papers focused on Dermatology and Skin Diseases (26 papers), Allergic Rhinitis and Sensitization (15 papers) and Urticaria and Related Conditions (9 papers). Kang Sun collaborates with scholars based in United States, Canada and China. Kang Sun's co-authors include Michael E. Kuligowski, Kim Papp, Michael Howell, Brian Kim, May E. Venturanza, Adnan Nasir, Hu Liu, Chuntai Liu, Changyu Shen and Eric L. Simpson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Kang Sun

52 papers receiving 1.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

2016 350 citations Claire Harrison, Alessandro M. Vannucchi et al. Leukemia profile →
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

2021 199 citations Kim Papp, Jacek C. Szepietowski et al. Journal of the American Academy of Dermatology profile →
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

2022 133 citations David Rosmarin, Thierry Passeron et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kang Sun United States	13	638	374	357	294	291	56	1.6k
David Chau United Kingdom	22	161 0.3×	36 0.1×	134 0.4×	29 0.1×	40 0.1×	57	1.8k
Lauren K. Macri United States	10	99 0.2×	69 0.2×	55 0.2×	39 0.1×	11 0.0×	13	998
Leo Wang United States	18	74 0.1×	23 0.1×	54 0.2×	60 0.2×	49 0.2×	61	2.1k
Georgios Theocharidis United States	16	107 0.2×	32 0.1×	158 0.4×	19 0.1×	9 0.0×	29	1.3k
Michael G. Monaghan Ireland	27	20 0.0×	25 0.1×	46 0.1×	92 0.3×	43 0.1×	59	1.9k
Devis Galesso Italy	17	46 0.1×	35 0.1×	25 0.1×	270 0.9×	15 0.1×	40	1.1k
Yunfan He China	19	113 0.2×	12 0.0×	323 0.9×	48 0.2×	9 0.0×	46	1.1k
Lisa A. Gurski United States	10	38 0.1×	69 0.2×	27 0.1×	40 0.1×	17 0.1×	11	1.2k
Svenja Hinderer Germany	17	65 0.1×	29 0.1×	52 0.1×	32 0.1×	13 0.0×	22	1.8k
Jung‐Ju Kim South Korea	22	97 0.2×	25 0.1×	90 0.3×	127 0.4×	12 0.0×	46	1.5k

Countries citing papers authored by Kang Sun

Since Specialization

Citations

This map shows the geographic impact of Kang Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kang Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kang Sun more than expected).

Fields of papers citing papers by Kang Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kang Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kang Sun. The network helps show where Kang Sun may publish in the future.

Co-authorship network of co-authors of Kang Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Kang Sun. A scholar is included among the top collaborators of Kang Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kang Sun. Kang Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Xiang, et al.. (2025). Evaluation of tensile strength variability in fiber reinforced composite rods using statistical distributions. Frontiers in Built Environment. 10. 2 indexed citations

Rosmarin, David, Thierry Passeron, Amit G. Pandya, et al.. (2025). Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publication. Therapeutic Advances in Chronic Disease. 16. 404426822–404426822.

Wang, Yinan, H.N. Anil Rao, Wendong Wang, et al.. (2025). Intrachain torsional disorder in melon-based carbon nitride aerogel with enhanced photocatalytic properties. Chemical Engineering Journal. 517. 164336–164336. 1 indexed citations

Xiong, Fangjie, et al.. (2024). An Oxidoreductase-like Protein is Required for Verticillium dahliae Infection and Participates in the Metabolism of Host Plant Defensive Compounds. Journal of Agricultural and Food Chemistry. 72(9). 4669–4678. 1 indexed citations

Yang, Xue, Jian Li, Y. Mao, et al.. (2024). A polyurethane solid-solid composite phase change material based on modified graphene oxide for efficient thermal management. Journal of Physics Conference Series. 2749(1). 12007–12007. 2 indexed citations

Li, Jian, et al.. (2024). Molecular dynamics simulation of thermal properties of modified graphene / n-octadecane composite phase change material. Journal of Physics Conference Series. 2749(1). 12008–12008. 1 indexed citations

Liu, Yue, Min Xi, Kang Sun, et al.. (2024). Effect of hygrothermal environment on fatigue performance of CFRP strands via experiment and molecular dynamics simulation. Journal of Building Engineering. 101. 111732–111732. 3 indexed citations

Howell, Michael, Fiona Kuo, Kang Sun, et al.. (2023). Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream. SHILAP Revista de lepidopterología. 3(6). 100230–100230. 1 indexed citations

Bissonnette, Robert, Lawrence F. Eichenfield, Eric L. Simpson, et al.. (2023). Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events. Journal of the European Academy of Dermatology and Venereology. 37(5). 976–983. 3 indexed citations

10.

Bloudek, Lisa, Lawrence F. Eichenfield, Jonathan I. Silverberg, et al.. (2022). Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies. American Journal of Clinical Dermatology. 24(1). 109–117. 7 indexed citations

11.

Hamzavi, Iltefat, David Rosmarin, John E. Harris, et al.. (2021). Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. Journal of the American Academy of Dermatology. 86(6). 1398–1401. 18 indexed citations

12.

Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2021). Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies. SKIN The Journal of Cutaneous Medicine. 5(1). s8–s8. 1 indexed citations

13.

Blauvelt, Andrew, Jacek C. Szepietowski, Kim Papp, et al.. (2021). 26884 Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: Pooled results from two phase 3 studies. Journal of the American Academy of Dermatology. 85(3). AB121–AB121. 9 indexed citations

14.

Simpson, Eric L., Robert Bissonnette, Michael E. Kuligowski, et al.. (2021). 311 Effects of ruxolitinib cream in patients with atopic dermatitis with head and/or neck involvement. Journal of Investigative Dermatology. 141(5). S55–S55. 2 indexed citations

15.

Owens, Sherry, et al.. (2019). 998 Ruxolitinib cream significantly modulates inflammatory profiles of atopic dermatitis patients. Journal of Investigative Dermatology. 139(5). S173–S173. 4 indexed citations

16.

Kim, Brian, Michael Howell, Kang Sun, et al.. (2019). Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. Journal of Allergy and Clinical Immunology. 145(2). 572–582. 165 indexed citations

17.

Harrison, Claire, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, et al.. (2016). Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 30(8). 1701–1707. 350 indexed citations breakdown →

18.

Sun, Kang, et al.. (2011). [Application of damage control surgery for severe abdominal trauma].. PubMed. 14(7). 506–8. 1 indexed citations

19.

Sun, Kang, et al.. (2005). Effects of Swiss Ball Exercise on Functional Fitness and Body Sway in Male Elderly Nursing Home Residents. The Korean Journal of Growth and Development. 13(1). 91–99. 1 indexed citations

20.

Xu, Zhifei, et al.. (2003). [Experimental study on a novel esophageal prosthesis made of composite biomaterials].. PubMed. 41(7). 541–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact